Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes

a case study

Hsih Te Yang, Hong Yang, Jung-Hsien Chiang, Shih Jon Wang

Research output: Contribution to journalReview article

Abstract

Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab–HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.

Original languageEnglish
Pages (from-to)1664-1671
Number of pages8
JournalDrug Discovery Today
Volume21
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Genomics
Human Influenza
Clinical Trials
Safety
Workflow
Antibodies
Hemagglutinins
Drug Discovery
Computational Biology
Communicable Diseases
Antigens
Therapeutics
Proteins

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

@article{9cf4a3544c4d4c3b84443371530479ea,
title = "Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study",
abstract = "Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab–HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.",
author = "Yang, {Hsih Te} and Hong Yang and Jung-Hsien Chiang and Wang, {Shih Jon}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.drudis.2016.06.008",
language = "English",
volume = "21",
pages = "1664--1671",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "10",

}

Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes : a case study. / Yang, Hsih Te; Yang, Hong; Chiang, Jung-Hsien; Wang, Shih Jon.

In: Drug Discovery Today, Vol. 21, No. 10, 01.10.2016, p. 1664-1671.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes

T2 - a case study

AU - Yang, Hsih Te

AU - Yang, Hong

AU - Chiang, Jung-Hsien

AU - Wang, Shih Jon

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab–HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.

AB - Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab–HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=84991402680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991402680&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2016.06.008

DO - 10.1016/j.drudis.2016.06.008

M3 - Review article

VL - 21

SP - 1664

EP - 1671

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 10

ER -